Boardroom Alpha
10-Q primary document
BTMD · Quarterly Report (Form 10-Q) · Filed November 7, 2025

Biote Corp10-Q exhibit

btmd-ex10_1.htm
EX-10.1

Exhibit 10.1

 

AMENDMENT TO SETTLEMENT AGREEMENT

 

This amendment (“Amendment”) to the Settlement Agreement attached as Exhibit A (“Agreement”), is made and entered into effective as of September 26, 2025. Capitalized terms used but not defined herein have the meanings ascribed to them in the Agreement.

 

WHEREAS, Biote has timely paid Donovitz forty million dollars ($40,000,000) of the Settlement Sum;

 

WHEREAS, Donovitz and Biote have agreed that Biote will make a lump sum payment of twelve million five hundred thousand dollars ($12,500,000) in full satisfaction of Biote’s obligation to pay the remaining portion of the Settlement Sum pursuant to the schedule set forth in Section 2 of the Agreement.

 

NOW, THEREFORE, in consideration of the below mutual promises and for other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties agree as follows:

 

1.
Payment. Sections 2.B.ii and 2.B.iii of the Agreement are hereby deleted in their entirety and replaced with the following: “Withing five (5) business days after the execution of this Amendment by all Parties, Biote will buy the remaining portion of Donovitz’s 8,293,220 shares/units from Donovitz for a cash payment of twelve million five hundred thousand dollars ($12,500,000.00).”

 

2.
Ownership of Shares/Units. Donovitz represents and warrants that: (a) Donovitz is the sole beneficial owner of the remaining portion of the 8,293,220 shares/units referenced in Section 1 of this Amendment, and (b) such shares/units have not been assigned, transferred, or otherwise encumbered them by way of subrogation, contract, operation of law or otherwise.

 

3.
Transfer of Shares/Units. Promptly (and in any event within five business days) after receipt of the payment set forth in Section 1 of this Amendment, Donovitz will either (i) deliver to Biote the certificate(s), if any, representing the Holdings Units, Class A Shares, and Class V Shares beneficially owned by Donovitz purchased thereby, together with any other necessary instruments of transfer (including a duly executed stock power); or (ii) initiate with the appropriate transfer agent the transfer of the Holdings Units, Class A Shares, and Class V Shares beneficially owned by Donovitz purchased thereby, together with any other necessary instruments of transfer (including a duly executed stock power). Biote and Holdings may update their books and records to reflect these transfers upon delivery of payment, without any further action by Donovitz.

 

4.
Continuation Of Agreement. Except as expressly modified by this Amendment, the Agreement (including all exhibits thereto) remains in full force and effect.

 

[REMAINDER OF PAGE LEFT BLANK]

 


 

IN WHITNESS WHEREOF, the Parties have executed this Amendment intending to make it a document under seal.

 

/s/ Marci M. Donovitz

 

/s/ Bret Christensen

MARCI M. DONOVITZ

 

BIOTE CORPORATION

 

 

 

/s/ Marci M. Donovitz

 

/s/ Bret Christensen

THE DONOVITZ FAMILY

 

BIOTE MEDICAL, LLC

IRREVOCABLE TRUST

 

 

 

 

/s/ Bret Christensen

 

 

BIOTE HOLDINGS, LLC

 

 

 

 

 

/s/ Marc D. Beer

 

 

MARC D. BEER

 

 

 

 

 

/s/ Teresa S. Weber

 

 

TERESA S. WEBER

 

 

 

 

 

/s/ Mary Elizabeth Conlon

 

 

MARY ELIZABETH CONLON

 

 

 

 

 

/s/ Andrew Heyer

 

 

HAYMAKER SPONSOR III LLC

 

 

 

 

 

/s/ Steven J. Heyer

 

 

STEVEN J. HEYER

 

 

 

 

 

/s/ Ann Mooney

 

 

COOLEY LLP

 

 

2

 


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer